Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
Become a Member | Sign in
Home>News>This Article

New Pain Test that Stratifies Patients for Optimal Therapy Seeks Partners

Published: Tuesday, February 19, 2013
Last Updated: Monday, February 18, 2013
Bookmark and Share
Algotect device measures an increased pain response to a cold stimulus.

A novel patented technology (Algotect) has been developed to accurately identify patients who are cold hyperalgesic and require specific pain management.

A recent Australian clinical trial (n=80) conducted with funding from a multi-national pharmaceutical company clearly segmented a group of knee osteoarthritis patients into those that had more pain, more disability, more widespread hyperalgesia and more neuropathic pain symptoms.

This group did not respond well to a standard non-steroidal medication. Cold hyperalgesic groups have been identified for a range of painful conditions and it is likely that these patients require more specific pain management.

More than 1.5 billion people worldwide suffer from chronic pain (American Academy of Pain Medicine) and around 100 million Americans suffer chronic pain (Institute of Medicine of the National Academies).

In developed countries about 30-40% of the population suffer pain from musculoskeletal and joint disorders plus an additional 30% suffer neck and back pain (International Association for the Study of Pain).

A chronic pain survey by the American Pain Foundation in 2006 (n=303) revealed 51% had little or no control over their pain and 59% reported an impact on their quality of life. The Algotect device identifies those most at risk of poor outcomes.

Managing Director and co-founder Prof Tony Wright comments, “There is an unmet medical need for a simple diagnostic test such as Algotect. Determining early on those patients who will develop chronic pain and providing them with more effective treatment will generate significant health outcomes for individuals and reduce costs on a global scale.”

The Algotect device measures an increased pain response to a cold stimulus (cold hyperalgesia). Patients who have cold hyperalgesia have more pain and more disability than others.

The prototype uses a transdermal patch that activates TRPM8 receptors in peripheral tissues over a 10-minute period. Patients indicate their sensory response via a computer interface.

A patented algorithm quantifies the sensory response and delivers a scored report indicating if their pain can be managed effectively through simple analgesics or if more comprehensive pain management is required.

Algometron seeks partners interested in commercially developing the innovative device, which provides real time, cost effective information to support clinicians, researchers, drug development and clinical trials.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Lucentis Effective for Proliferative Diabetic Retinopathy
NIH-funded clinical trial marks first major advance in therapy in 40 years.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.
First Therapy Appearing to Reverse Decline in Parkinson’s
An FDA-approved drug for leukemia improved cognition, motor skills and non-motor function in patients with Parkinson’s disease and Lewy body dementia in a small clinical trial, say researchers at Georgetown University Medical Center (GUMC).
Gene Therapy Staves Off Blindness from Retinitis Pigmentosa in Canine Model
NIH-funded study suggests therapeutic window may extend to later-stage disease.
Treatment for Rare Bleeding Disorder is Effective
Researchers in Manchester have demonstrated for the first time the relative safety and effectiveness of treatment, eltrombopag, in children with persistent or chronic immune thrombocytopenia (ITP), as part of an international duo of studies.
HIV Vaccine Human Trials Begin
Baltimore-based Institute has begun enrolling volunteers for initial phase 1 clinical trials.
New Therapy Reduces Symptoms of Inherited Enzyme Deficiency
A phase three clinical trial of a new enzyme replacement medication, sebelipase alfa, showed a reduction in multiple disease-related symptoms in children and adults with lysosomal acid lipase deficiency, an inherited enzyme deficiency that can result in scarring of the liver and high cholesterol.
Fixing Holes in the Heart Without Invasive Surgery
UV-light enabled catheter is a medical device which represents a major shift in how cardiac defects are repaired.
Atriva Therapeutics GmbH Develops Innovative Flu Drug
Highly effective against seasonal and pandemic influenza.
Study Removes Cancer Doubt for Multiple Sclerosis Drug
Researchers from Queen Mary University of London are calling on the medical community to reconsider developing a known drug to treat people with relapsing Multiple sclerosis after new evidence shows it does not increase the risk of cancer as previously thought.
Scroll Up
Scroll Down

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos